Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iGlarLixi vs Insulin Glargine in Type 2 Diabetes Mellitus (China, Phase III)
CTR20181387Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Feb 2019; status: completed.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20181387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181387.